Correlation between HPV infection and clinicopathologic features of patients
Characteristics
Effective
HPV-positive
P
Samples number (n)
Percentage (%)
Age at diagnosis (year)
27–41
15
12
80.00
0.081
42–61
45
41
91.11
> 61
20
20
100.00
Histological type
SCC
66
61
92.42
0.600
Adenocarcinoma
14
12
85.71
FIGO clinical stage
I
16
14
87.50
0.511
II
57
53
92.98
III
7
6
85.71
IV
0
0
–
ABO blood group
A+
17
15
88.24
0.277
A–
5
5
100.00
B+
11
10
90.91
B–
7
5
71.43
AB+
2
2
100.00
AB–
0
0
–
O+
32
31
96.88
O–
6
5
83.33
Age at menarche (in years)
≤ 12
55
53
96.36
0.028
> 12
25
20
80.00
Menopause
Yes
54
51
94.44
0.206
No
26
22
84.62
Age at menopause (in years)
< 45
14
14
100.00
0.560
≥ 45
40
37
92.50
Parity
Yes
70
67
95.71
0.004
No
10
6
60.00
Number of children
1–2
30
28
93.33
0.573
≥ 3
40
39
97.50
Childbirth delivery
Vaginal birth
59
56
94.92
0.040
Caesarean section
11
8
72.73
Oral contraceptives use
Yes
56
53
94.64
0.189
No
24
20
83.33
Duration of oral contraceptives use (in years)
≥ 5
33
32
96.97
0.562
< 5
23
21
91.30
Residence area
Urban and sub-urban
58
52
89.66
0.667
Rural
22
21
95.45
Marital status
Single (separated or widowed)
18
14
77.78
0.042
Married
62
59
95.16
Health insurance
Covered (RAMED)
75
69
92.00
0.375
Not covered
5
4
80.00
RAMED: Regime d’Assistance Medicale; –: not applicable
Declarations
Acknowledgments
Special acknowledgment for Faculty of Sciences and Techniques of Mohammedia, University Hassan II of Casablanca and Ministry of Higher Education, Scientific Research and Innovation in Morocco.
The authors declare that they have no conflicts of interest.
Ethical approval
The study protocol was approved by the Ethics Committee for Biomedical Research of the Faculty of Medicine and Pharmacy of Casablanca, Morocco (Reference 3/2018 on 30.04.2018).
Consent to participate
The informed consent to participate in the study was obtained from all participants.
Consent to publication
Not applicable.
Availability of data and materials
The datasets generated and/or analyzed in the course of the present study are available from the corresponding author upon reasonable request.
Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget J, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers.J Natl Cancer Inst. 1990;82:1477–84. [DOI] [PubMed]
Lee SH, Vigliotti VS, Vigliotti JS, Pappu S. Validation of human papillomavirus genotyping by signature DNA sequence analysis.BMC Clin Pathol. 2009;9:3. [DOI] [PubMed] [PMC]
Boumba LM, Assoumou SZ, Hilali L, Mambou JV, Moukassa D, Ennaji MM. Genetic variability in E6 and E7 oncogenes of human papillomavirus Type 16 from Congolese cervical cancer isolates.Infect Agent Cancer. 2015;10:15. [DOI] [PubMed] [PMC]
Dictor M, Warenholt J. Single-tube multiplex PCR using type-specific E6/E7 primers and capillary electrophoresis genotypes 21 human papillomaviruses in neoplasia.Infect Agent Cancer. 2011;6:1. [DOI] [PubMed] [PMC]
Lindh M, Görander S, Andersson E, Horal P, Mattsby-Balzer I, Ryd W. Real-time Taqman PCR targeting 14 human papilloma virus types.J Clin Virol. 2007;40:321–4. [DOI] [PubMed]
Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus.J Clin Microbiol. 1996;34:2095–100. [DOI] [PubMed] [PMC]
Amrani M, Lalaoui K, El Mzibri M, Lazo P, Belabbas MA. Molecular detection of human papillomavirus in 594 uterine cervix samples from Moroccan women (147 biopsies and 447 swabs).J Clin Virol. 2003;27:286–95. [DOI] [PubMed]
Khair MM, Mzibri ME, Mhand RA, Benider A, Benchekroun N, Fahime EM, et al. Molecular detection and genotyping of human papillomavirus in cervical carcinoma biopsies in an area of high incidence of cancer from Moroccan women.J Med Virol. 2009;81:678–84. [DOI] [PubMed]
Yang ST, Liu CH, Wang PH. No impact of tumor size on oncological outcomes in cervical cancer patients after radical hysterectomy and postoperative radiotherapy: Is it real?Taiwan J Obstet Gynecol. 2022;61:575–7. [DOI] [PubMed]
Saxsena S, Gupta KK. Association of ABO blood groups in relation to gynaecological cancers in Western Rajasthan.Int J Health Sci Res. 2016;6:118–24.
Yuzhalin AE, Kutikhin AG. ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia.Asian Pac J Cancer Prev. 2012;13:5091–6. [DOI] [PubMed]
Ghali BE, Mohammed O, Hicham Y, Mustapha AA. Phenotypic and genotypic frequencies of ABO and Rh systems in the Moroccan population: study carried out in the blood transfusion service at the Avicenne Military Hospital, Marrakech.PAMJ Clin Med. 2020;2:140. French. [DOI]
Elasbali AM, El Din AH, Abdallah RA, Ahmed HG. Cervical and oral screening for HR-HPV types 16 and 18 among sudanese women cervical lesions.Infect Agent Cancer. 2012;7:17. [DOI] [PubMed] [PMC]
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.J Infect Dis. 2010;202:1789–99. [DOI] [PubMed]
Wang X, Song Y, Wei X, Wang G, Sun R, Wang M, et al. Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China.Virol J. 2022;19:6. [DOI] [PubMed] [PMC]
El Maazouzi S. Genotypes du papillomavirus humain circulant chez les femmes de la region de kenitra [dissertation]. Rabat: Mohammed V University; 2020. French.
Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against cancer.Vaccines (Basel). 2021;9:1413. [DOI] [PubMed] [PMC]
Mwaka AD, Orach CG, Were EM, Lyratzopoulos G, Wabinga H, Roland M. Awareness of cervical cancer risk factors and symptoms: cross-sectional community survey in post-conflict northern Uganda.Health Expect. 2016;19:854–67. [DOI] [PubMed] [PMC]
Taky-eddine AS. Depistage et genotypage du papillomavirus humain dans la region de rabat- kenitra [dissertation]. Rabat: Mohammed V University; 2019. French.
McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers.PLoS Pathog. 2017;13:e1006211. [DOI] [PubMed] [PMC]
Kennedy NT, Ikechukwu D, Goddy B. Risk factors and distribution of oncogenic strains of human papilloma virus in women presenting for cervical cancer screening in Port Harcourt, Nigeria.Pan Afr Med J. 2016;23:85. [DOI] [PubMed] [PMC]
Belglaiaa E. Génotypage moléculaire des papillomavirus humains chez des femmes à risque de cancer du col de l’utérus: implication pour le dépistage et la prevention [dissertation]. Agadir: Université Bourgogne Franche-Comté; 2015. French.
Berraho M, Amarti-Riffi A, El-Mzibri M, Bezad R, Benjaafar N, Benideer A, et al. HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study.BMC cancer. 2017;17:435. [DOI] [PubMed] [PMC]
Kuguyo O, Dube Mandishora RS, Thomford NE, Makunike-Mutasa R, Nhachi CFB, Matimba A, et al. High-risk HPV genotypes in Zimbabwean women with cervical cancer: comparative analyses between HIV-negative and HIV-positive women.PLoS One. 2021;16:e0257324. [DOI] [PubMed] [PMC]
Arroyo Mühr LS, Eklund C, Dillner J. Misclassifications in human papillomavirus databases.Virology. 2021;558:57–66. [DOI] [PubMed]
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med. 2003;348:518–27. [DOI] [PubMed]
Giannini A, Donato VD, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, et al. Outcomes of high-grade cervical dysplasia with positive margins and HPV persistence after cervical conization.Vaccines. 2023;11:698. [DOI] [PubMed] [PMC]
Bogani G, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Lopez S, et al. Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: a 5-year follow-up study.Gynecol Oncol. 2020;159:636–41. [DOI] [PubMed]
Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Giannini A, et al. Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia.Eur J Cancer Prev. 2023;32:525–32. [DOI] [PubMed]
Ahmed HG, Bensumaidea SH, Ashankyty IM. Frequency of Human Papilloma Virus (HPV) subtypes 31,33,35,39 and 45 among Yemeni women with cervical cancer.Infect Agent Cancer. 2015;10:29. [DOI] [PubMed] [PMC]
Vaillant-Roussel H, Cadwallader JS. HPV testing could reduce cervical cancer by one-third.Exercer-La Revue Francophone de Medecine Generale. 2013;24:239. French.
